TMOD3

Summary

TMOD3 (tropomodulin 3, HGNC:11873) is a protein-coding gene on chromosome 15q21.2, encoding Tropomodulin-3 (Q9NYL9). Blocks the elongation and depolymerization of the actin filaments at the pointed end.

Enables cadherin binding activity involved in cell-cell adhesion. Predicted to be involved in actin filament organization; muscle contraction; and myofibril assembly. Predicted to act upstream of or within actin cytoskeleton organization; erythrocyte development; and positive regulation of mitotic cell cycle phase transition. Located in adherens junction.

Source: NCBI Gene 29766 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 60 total
• MANE Select transcript: NM_014547

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11873
Approved symbol	TMOD3
Name	tropomodulin 3
Location	15q21.2
Locus type	gene with protein product
Status	Approved
Aliases	UTMOD
Ensembl gene	ENSG00000138594
Ensembl biotype	protein_coding
OMIM	605112
Entrez	29766

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 12 protein_coding, 7 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000308580, ENST00000558300, ENST00000558455, ENST00000558666, ENST00000558714, ENST00000559202, ENST00000560549, ENST00000560725, ENST00000561136, ENST00000561408, ENST00000561438, ENST00000871168, ENST00000871169, ENST00000871170, ENST00000871171, ENST00000871172, ENST00000871173, ENST00000871174, ENST00000924675, ENST00000924676, ENST00000961498

RefSeq mRNA: 1 — MANE Select: NM_014547 NM_014547

CCDS: CCDS10145

Canonical transcript exons

ENST00000308580 — 10 exons

Exon	Start	End
ENSE00000931404	51869217	51869373
ENSE00001102821	51893815	51893945
ENSE00001170748	51862811	51863010
ENSE00001243138	51908776	51915725
ENSE00001637299	51896419	51896526
ENSE00001654862	51900155	51900298
ENSE00002540197	51829653	51829836
ENSE00003479780	51901892	51902036
ENSE00003649448	51889056	51889145
ENSE00003676764	51887589	51887711

Expression profiles

Bgee: expression breadth ubiquitous, 268 present calls, max score 97.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 49.0555 / max 642.6341, expressed in 1819 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146683	42.2696	1817
146684	3.1800	1347
146682	2.4564	1342
146690	0.3872	136
146685	0.3428	143
146691	0.1869	54
146696	0.1134	44
146695	0.0939	37
146686	0.0252	4

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
amniotic fluid	UBERON:0000173	97.62	gold quality
esophagus squamous epithelium	UBERON:0006920	96.60	gold quality
oral cavity	UBERON:0000167	96.21	gold quality
buccal mucosa cell	CL:0002336	95.76	gold quality
gingiva	UBERON:0001828	95.03	gold quality
lower lobe of lung	UBERON:0008949	94.95	gold quality
lower esophagus mucosa	UBERON:0035834	94.76	gold quality
gingival epithelium	UBERON:0001949	94.63	gold quality
colonic epithelium	UBERON:0000397	94.23	gold quality
skin of hip	UBERON:0001554	93.65	gold quality
calcaneal tendon	UBERON:0003701	93.34	gold quality
epithelium of esophagus	UBERON:0001976	93.13	gold quality
mucosa of sigmoid colon	UBERON:0004993	92.77	gold quality
pharyngeal mucosa	UBERON:0000355	92.60	gold quality
esophagus mucosa	UBERON:0002469	92.45	gold quality
penis	UBERON:0000989	92.41	gold quality
colonic mucosa	UBERON:0000317	91.92	gold quality
tendon of biceps brachii	UBERON:0008188	91.51	gold quality
tonsil	UBERON:0002372	91.15	gold quality
tendon	UBERON:0000043	91.10	gold quality
sperm	CL:0000019	91.08	gold quality
visceral pleura	UBERON:0002401	90.34	gold quality
monocyte	CL:0000576	90.10	gold quality
upper leg skin	UBERON:0004262	90.07	gold quality
jejunal mucosa	UBERON:0000399	89.85	gold quality
stromal cell of endometrium	CL:0002255	89.57	gold quality
mononuclear cell	CL:0000842	89.36	gold quality
leukocyte	CL:0000738	89.26	gold quality
palpebral conjunctiva	UBERON:0001812	89.08	gold quality
parietal pleura	UBERON:0002400	89.05	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.29
E-GEOD-130148	yes	5.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

170 targeting TMOD3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548N	99.98	71.94	4170

Literature-anchored findings (GeneRIF, showing 10)

• capping of actin filament pointed ends by Tmod3 inhibits cell migration and reveal a novel control mechanism for regulation of actin filaments in lamellipodia. (PMID:12707310)
• levels of TM1, TM2 and TM3 are reduced in human transitional cell carcinoma cells, but significantly upregulated by inhibition of the mitogen-activated protein kinase-signaling pathway (PMID:15095301)
• the Tmod3 isoform may regulate actin dynamics differently in cells than the previously described tropomodulin isoforms (PMID:17012745)
• findings show that the pointed-end capping protein Tmod3 contributes to epithelial cell shape within confluent monolayers of polarized epithelial cells (PMID:17928307)
• investigation of biomarkers for early diagnosis of endometriosis: Data suggest that TMOD3, tropomyosin 3, and stomatin-like protein 2 are autoantigens present in blood of women with endometriosis; immunodominant epitopes were identified. (PMID:22158085)
• study has identified several new proteins like RHOC, DLG5, UGDH, TMOD3 in addition to known chemoresistance associated proteins in non-small cell lung carcinoma. (PMID:26898345)
• TMOD3 expression was found to be elevated in liver cancer cells and tissues. In the in vitro experiments, liver cancer cell proliferation, invasion and migration were inhibited by TMOD3 knockdown and promoted by ectopic expression of TMOD3. TMOD3 overexpression activated MAPK/ERK signaling and increased the levels of other targets of this pathway. (PMID:30864730)
• These findings reveal that Tmod3 enhances aggressive behavior of hepatocellular carcinoma (HCC) both in vitro and in vivo by interacting with EFGR and by activating the PI3K-AKT signaling pathway. (PMID:31313392)
• Tropomodulins Control the Balance between Protrusive and Contractile Structures by Stabilizing Actin-Tropomyosin Filaments. (PMID:32037094)
• Clinicopathological Characteristics, Prognosis, and Correlated Tumor Cell Function of Tropomodulin-3 in Pancreatic Adenocarcinoma. (PMID:37563820)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmod2	ENSDARG00000002571
mus_musculus	Tmod3	ENSMUSG00000058587
rattus_norvegicus	Tmod3	ENSRNOG00000032436
drosophila_melanogaster	tmod	FBGN0082582
caenorhabditis_elegans	unc-94	WBGENE00006823

Paralogs (6): TMOD2 (ENSG00000128872), TMOD1 (ENSG00000136842), TMOD4 (ENSG00000163157), LMOD3 (ENSG00000163380), LMOD1 (ENSG00000163431), LMOD2 (ENSG00000170807)

Protein

Protein identifiers

Tropomodulin-3 — Q9NYL9 (reviewed: Q9NYL9)

Alternative names: Ubiquitous tropomodulin

All UniProt accessions (4): Q9NYL9, H0YKU1, H0YNJ8, H0YNU8

UniProt curated annotations — full annotation on UniProt →

Function. Blocks the elongation and depolymerization of the actin filaments at the pointed end. The Tmod/TM complex contributes to the formation of the short actin protofilament, which in turn defines the geometry of the membrane skeleton.

Subunit / interactions. Binds to the N-terminus of tropomyosin and to actin. Interacts with FLII.

Subcellular location. Cytoplasm. Cytoskeleton.

Tissue specificity. Ubiquitous.

Similarity. Belongs to the tropomodulin family.

RefSeq proteins (1): NP_055362* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004934	TMOD	Family
IPR032675	LRR_dom_sf	Homologous_superfamily

Pfam: PF03250

UniProt features (3 total): chain 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NYL9-F1	82.10	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 25

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-390522	Striated Muscle Contraction
R-HSA-9013418	RHOBTB2 GTPase cycle
R-HSA-9696264	RND3 GTPase cycle

MSigDB gene sets: 289 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, RRAGTTGT_UNKNOWN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_MYELOID_CELL_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_ERYTHROCYTE_HOMEOSTASIS, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, AP4_Q6, GOBP_NEGATIVE_REGULATION_OF_ACTIN_FILAMENT_DEPOLYMERIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS

GO Biological Process (9): muscle contraction (GO:0006936), actin filament organization (GO:0007015), myofibril assembly (GO:0030239), mitotic cell cycle phase transition (GO:0044772), erythrocyte development (GO:0048821), pointed-end actin filament capping (GO:0051694), positive regulation of mitotic cell cycle phase transition (GO:1901992), actin cytoskeleton organization (GO:0030036), cell-cell adhesion (GO:0098609)

GO Molecular Function (4): actin binding (GO:0003779), tropomyosin binding (GO:0005523), cadherin binding involved in cell-cell adhesion (GO:0098641), protein binding (GO:0005515)

GO Cellular Component (5): cytoskeleton (GO:0005856), striated muscle thin filament (GO:0005865), adherens junction (GO:0005912), myofibril (GO:0030016), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Muscle contraction	1
RHOBTB GTPase Cycle	1
RHO GTPase cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
supramolecular fiber organization	2
cytoskeletal protein binding	2
muscle system process	1
actin cytoskeleton organization	1
cellular component assembly involved in morphogenesis	1
actomyosin structure organization	1
striated muscle cell development	1
membraneless organelle assembly	1
mitotic cell cycle	1
cell cycle phase transition	1
mitotic cell cycle process	1
erythrocyte differentiation	1
myeloid cell development	1
actin filament capping	1
mitotic cell cycle phase transition	1
positive regulation of mitotic cell cycle	1
positive regulation of cell cycle phase transition	1
regulation of mitotic cell cycle phase transition	1
cytoskeleton organization	1
actin filament-based process	1
cell adhesion	1
cadherin binding	1
cell-cell adhesion	1
cell-cell adhesion mediator activity	1
binding	1
intracellular membraneless organelle	1
actin cytoskeleton	1
sarcomere	1
myofilament	1
cell-cell junction	1
contractile muscle fiber	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1180 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMOD3	ADD1	P35611	955
TMOD3	ADD2	P35612	945
TMOD3	ADD3	Q9UEY8	939
TMOD3	NEB	P20929	917
TMOD3	CGNL1	Q0VF96	906
TMOD3	DMTN	Q08495	894
TMOD3	CARMIL2	Q6F5E8	847
TMOD3	EPB41	P11171	821
TMOD3	ANK1	P16157	801
TMOD3	CAPZA2	P47755	798
TMOD3	CAPZA1	P52907	796
TMOD3	CYP19A1	P11511	735
TMOD3	MYPN	Q86TC9	724
TMOD3	ANK2	Q01484	708
TMOD3	ANK3	Q12955	693

IntAct

178 interactions, top by confidence:

A	B	Type	Score
PRPF3	PRPF4	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
DAPK1	MYO1B	psi-mi:“MI:0914”(association)	0.530
LIN9	MYBL1	psi-mi:“MI:0914”(association)	0.530
TWF1	MYO1C	psi-mi:“MI:0914”(association)	0.530
SSH1	GSN	psi-mi:“MI:0914”(association)	0.530
DBN1	SVIL	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
FOS	MYO1C	psi-mi:“MI:2364”(proximity)	0.480
TMOD3	CSNK2A1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
Tubgcp3		psi-mi:“MI:0915”(physical association)	0.400
Cbx1	FLOT1	psi-mi:“MI:0915”(physical association)	0.400
Cdk1		psi-mi:“MI:0915”(physical association)	0.400
Poc1b		psi-mi:“MI:0915”(physical association)	0.400
Pafah1b1	EDIL3	psi-mi:“MI:0915”(physical association)	0.400
Erh	BCLAF3	psi-mi:“MI:0915”(physical association)	0.400
Stag2	PPP1R12A	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (362): TMOD3 (Affinity Capture-MS), TMOD3 (Affinity Capture-MS), TMOD3 (Affinity Capture-MS), ATP6V1B2 (Co-fractionation), MCFD2 (Co-fractionation), PAM16 (Co-fractionation), RUVBL2 (Co-fractionation), SMARCC1 (Co-fractionation), SMARCC2 (Co-fractionation), SNRPD1 (Co-fractionation), TMOD3 (Co-fractionation), TMOD3 (Co-fractionation), TMOD3 (Co-fractionation), TMOD3 (Co-fractionation), TMOD3 (Co-fractionation)

ESM2 similar proteins: A0A1L8G016, A1A5Q0, B3DH20, D3Z8X7, D4A1F2, E1BTG2, F1MF74, F1RA39, O14730, O60308, O88978, O94851, O95801, P51432, P70566, Q1RMR5, Q1RMT7, Q28FY0, Q2YDM7, Q3UHZ5, Q3UM18, Q4KLT3, Q4R3F0, Q4R8L2, Q5BJT6, Q5EA11, Q5ZJD3, Q6AZN0, Q6P5Q4, Q7Z569, Q80V31, Q863A4, Q863A5, Q863A6, Q863A7, Q86X45, Q8BML1, Q8CCP0, Q8R368, Q8R3H9

Diamond homologs: A0A0G2K0D3, A0JNC0, A1A5Q0, E1BTG2, E7F7X0, E9QA62, O01479, P28289, P29536, P49813, P70566, P70567, Q0VAK6, Q0VC48, Q3UHZ5, Q6P5Q4, Q8BVA4, Q9JHJ0, Q9JKK7, Q9JLH8, Q9NYL9, Q9NZQ9, Q9NZR1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 187 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RHO GTPases activate PAKs	6	28.6×	4e-05
Signaling by RAS mutants	5	18.6×	2e-03
RHO GTPases activate IQGAPs	5	15.2×	3e-03
Sensory processing of sound	5	13.5×	3e-03
Signaling by FGFR1 in disease	5	12.8×	3e-03
Signaling by RAF1 mutants	5	12.2×	4e-03
Signaling by moderate kinase activity BRAF mutants	5	11.1×	4e-03
Paradoxical activation of RAF signaling by kinase inactive BRAF	5	11.1×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
barbed-end actin filament capping	6	31.7×	2e-05
actin filament-based movement	5	26.4×	5e-04
actin polymerization or depolymerization	5	25.2×	5e-04
platelet aggregation	5	11.1×	1e-02
actin filament organization	12	9.4×	8e-06
cellular response to type II interferon	6	8.2×	1e-02
actin cytoskeleton organization	11	5.7×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2545 predictions. Top by Δscore:

Variant	Effect	Δscore
15:51829834:CAGG:C	donor_loss	1.0000
15:51829835:AGG:A	donor_loss	1.0000
15:51829837:G:C	donor_loss	1.0000
15:51835055:T:G	donor_gain	1.0000
15:51862806:CATA:C	acceptor_loss	1.0000
15:51862808:TAGC:T	acceptor_loss	1.0000
15:51862809:A:AG	acceptor_gain	1.0000
15:51862809:A:C	acceptor_loss	1.0000
15:51862810:G:GC	acceptor_loss	1.0000
15:51862810:G:GG	acceptor_gain	1.0000
15:51863010:GGTA:G	donor_loss	1.0000
15:51863011:GTA:G	donor_loss	1.0000
15:51863012:T:A	donor_loss	1.0000
15:51869372:AGGT:A	donor_loss	1.0000
15:51869374:G:GA	donor_loss	1.0000
15:51869374:G:GG	donor_gain	1.0000
15:51869375:T:G	donor_loss	1.0000
15:51887584:TACA:T	acceptor_loss	1.0000
15:51887586:CAGG:C	acceptor_loss	1.0000
15:51887587:A:AG	acceptor_gain	1.0000
15:51887588:G:A	acceptor_loss	1.0000
15:51887588:G:GG	acceptor_gain	1.0000
15:51887711:GG:G	donor_loss	1.0000
15:51887713:T:G	donor_loss	1.0000
15:51887729:T:G	donor_gain	1.0000
15:51889050:TTATA:T	acceptor_loss	1.0000
15:51889051:TATA:T	acceptor_loss	1.0000
15:51889052:ATAG:A	acceptor_loss	1.0000
15:51889053:TA:T	acceptor_loss	1.0000
15:51889054:A:AC	acceptor_loss	1.0000

AlphaMissense

2341 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:51900214:C:A	N265K	0.999
15:51900214:C:G	N265K	0.999
15:51896506:A:C	S239R	0.998
15:51896508:C:A	S239R	0.998
15:51896508:C:G	S239R	0.998
15:51900213:A:T	N265I	0.995
15:51869296:T:C	L69P	0.994
15:51896522:C:A	A244D	0.994
15:51900209:T:C	S264P	0.994
15:51901976:T:C	F322L	0.994
15:51901978:T:A	F322L	0.994
15:51901978:T:G	F322L	0.994
15:51900298:G:C	Q293H	0.993
15:51900298:G:T	Q293H	0.993
15:51902012:G:C	A334P	0.993
15:51908778:C:A	R343S	0.993
15:51869319:G:C	A77P	0.992
15:51896519:T:A	V243D	0.992
15:51900212:A:T	N265Y	0.992
15:51900215:T:C	F266L	0.992
15:51900217:T:A	F266L	0.992
15:51900217:T:G	F266L	0.992
15:51901977:T:C	F322S	0.992
15:51893932:T:C	L205S	0.991
15:51893939:T:A	N207K	0.991
15:51893939:T:G	N207K	0.991
15:51901995:G:C	R328P	0.991
15:51862979:T:C	L32P	0.990
15:51887673:T:C	L123S	0.990
15:51893936:T:A	N206K	0.990

dbSNP variants (sampled 300 via entrez): RS1000063084 (15:51862492 A>G), RS1000074884 (15:51832575 T>G), RS1000087447 (15:51909772 A>G), RS1000092852 (15:51892312 A>G), RS1000118425 (15:51877156 A>G), RS1000184533 (15:51880199 A>G), RS1000198182 (15:51861855 C>G,T), RS1000222442 (15:51885341 G>C), RS1000224434 (15:51900986 C>T), RS1000252743 (15:51843423 A>G,T), RS1000290989 (15:51856946 G>A,T), RS1000294377 (15:51849899 A>G), RS1000299360 (15:51901343 A>G), RS1000374896 (15:51850137 T>C), RS1000399712 (15:51856054 G>A)

Disease associations

OMIM: gene MIM:605112 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation, increases expression	3
Air Pollutants	affects expression, increases abundance, decreases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression, affects localization, increases expression	1
bufalin	decreases expression	1
potassium chromate(VI)	decreases expression	1
cupric oxide	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	increases expression	1
bisphenol AF	increases expression	1
Acetaminophen	increases expression	1
Caffeine	affects phosphorylation	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Furaldehyde	affects cotreatment, increases expression	1
Haloperidol	decreases expression	1
Ozone	affects expression, increases abundance	1
Phenobarbital	affects expression	1
Rotenone	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2IV	Abcam HeLa TMOD3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.